Under construction – not a live service
Sign in
Taking people in GermanyNo phase

Follows adults with relapsing multiple sclerosis on approved injectable and oral treatments

Observes patients with relapsing multiple sclerosis taking approved injectable or oral medicines in Germany.

Plain-language title generated from the registry record
Registry title: A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis

Key facts

Where
Aalen, Albstadt, Altenburg, Altenholz, Altmark, Alzey, Bad Homburg, Bamberg, Bayreuth, Bergneustadt, Berlin, Böblingen, Bochum, Bogen, Bonn, Braunschweig, Bremen, Chemnitz, Coburg, Cologne, Crailsheim, Dessau, Dillingen an der Donau, Dillingen Saar, Dortmund, Dresden, Duisburg, Düsseldorf, Eisleben Lutherstadt, Eltville, Erbach im Odenwald, Erfurt, Erlangen, Essen, Falkensee, Frankfurt am Main, Fulda, Gelsenkirchen, Giessen, Gladenbach, Görlitz, Hagen, Halle, Hamburg, Hanover, Hettingen, Höxter, Ingelheim, Itzehoe, Jena, Kaiserslautern, Karlsruhe, Leipzig, Lünen, Magdeburg, Mannheim, Marburg, Meerbusch, Merzig, Mettmann, Minden, Montabaur, Mühlhausen, Mülheim, München, Munich, Münster, Nagold, Neuburg A.d. Donau, Neuruppin, Nuremberg, Oer-Erkenschwick, Oldenburg, Osnabrück, Pforzheim, Potsdam, Regensburg, Remscheid, Rostock, Rüdersdorf, Rülzheim, Saarlouis, Salzatal, Schiltach, Schneverdingen, Schwäbisch Hall, Schwetzingen, Siegen, Sinsheim, Stadtroda, Stuttgart, Tirschenreuth, Trier, Tübingen, Unterhaching, Untermeitingen, Velbert, Weil der Stadt, Wildeshausen, and Wolfratshausen, GermanySee the 100 sites

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 100 years old?

Source: NCT05344469, who can take part

Where in Germany

  • AalenAalen, GermanyTaking people
  • AlbstadtAlbstadt, GermanyTaking people
  • AltenburgAltenburg, GermanyNo longer taking part
  • AltenholzAltenholz, GermanyTaking people
  • AltmarkAltmark, GermanyNo longer taking part
  • AlzeyAlzey, GermanyNo longer taking part
  • Bad HomburgBad Homburg, GermanyTaking people
  • BambergBamberg, GermanyNo longer taking part
  • BayreuthBayreuth, GermanyNo longer taking part
  • BergneustadtBergneustadt, GermanyNo longer taking part
  • BerlinBerlin, GermanyNo longer taking part
  • BöblingenBöblingen, GermanyTaking people
  • BochumBochum, GermanyTaking people
  • BogenBogen, GermanyTaking people
  • BonnBonn, GermanyTaking people
  • BraunschweigBraunschweig, GermanyTaking people
  • BremenBremen, GermanyNo longer taking part
  • ChemnitzChemnitz, GermanyNo longer taking part
  • CoburgCoburg, GermanyTaking people
  • CologneCologne, GermanyTaking people
  • CrailsheimCrailsheim, GermanyTaking people
  • DessauDessau, GermanyTaking people
  • Dillingen an der DonauDillingen an der Donau, GermanyNo longer taking part
  • Dillingen SaarDillingen Saar, GermanyTaking people
  • DortmundDortmund, GermanyTaking people
  • DresdenDresden, GermanyTaking people
  • DuisburgDuisburg, GermanyNo longer taking part
  • DüsseldorfDüsseldorf, GermanyTaking people
  • Eisleben LutherstadtEisleben Lutherstadt, GermanyTaking people
  • EltvilleEltville, GermanyTaking people
  • Erbach im OdenwaldErbach im Odenwald, GermanyTaking people
  • ErfurtErfurt, GermanyTaking people
  • ErlangenErlangen, GermanyTaking people
  • EssenEssen, GermanyNo longer taking part
  • FalkenseeFalkensee, GermanyNo longer taking part
  • Frankfurt am MainFrankfurt am Main, GermanyNo longer taking part
  • FuldaFulda, GermanyNo longer taking part
  • GelsenkirchenGelsenkirchen, GermanyTaking people
  • GiessenGiessen, GermanyTaking people
  • GladenbachGladenbach, GermanyTaking people
  • GörlitzGörlitz, GermanyTaking people
  • HagenHagen, GermanyNo longer taking part
  • HalleHalle, GermanyTaking people
  • HamburgHamburg, GermanyTaking people
  • HanoverHanover, GermanyNo longer taking part
  • HettingenHettingen, GermanyNo longer taking part
  • HöxterHöxter, GermanyTaking people
  • IngelheimIngelheim, GermanyNo longer taking part
  • ItzehoeItzehoe, GermanyNo longer taking part
  • JenaJena, GermanyTaking people
  • KaiserslauternKaiserslautern, GermanyTaking people
  • KarlsruheKarlsruhe, GermanyNo longer taking part
  • LeipzigLeipzig, GermanyNo longer taking part
  • LünenLünen, GermanyNo longer taking part
  • MagdeburgMagdeburg, GermanyTaking people
  • MannheimMannheim, GermanyTaking people
  • MarburgMarburg, GermanyNo longer taking part
  • MeerbuschMeerbusch, GermanyTaking people
  • MerzigMerzig, GermanyTaking people
  • MettmannMettmann, GermanyNo longer taking part
  • MindenMinden, GermanyNo longer taking part
  • MontabaurMontabaur, GermanyNo longer taking part
  • MühlhausenMühlhausen, GermanyTaking people
  • MülheimMülheim, GermanyNo longer taking part
  • MünchenMünchen, GermanyTaking people
  • MunichMunich, GermanyNo longer taking part
  • MünsterMünster, GermanyNo longer taking part
  • NagoldNagold, GermanyTaking people
  • Neuburg A.d. DonauNeuburg A.d. Donau, GermanyNo longer taking part
  • NeuruppinNeuruppin, GermanyNo longer taking part
  • NurembergNuremberg, GermanyNo longer taking part
  • Oer-ErkenschwickOer-Erkenschwick, GermanyNo longer taking part
  • OldenburgOldenburg, GermanyTaking people
  • OsnabrückOsnabrück, GermanyTaking people
  • PforzheimPforzheim, GermanyTaking people
  • PotsdamPotsdam, GermanyNo longer taking part
  • RegensburgRegensburg, GermanyNo longer taking part
  • RemscheidRemscheid, GermanyTaking people
  • RostockRostock, GermanyNo longer taking part
  • RüdersdorfRüdersdorf, GermanyNo longer taking part
  • RülzheimRülzheim, GermanyTaking people
  • SaarlouisSaarlouis, GermanyNo longer taking part
  • SalzatalSalzatal, GermanyTaking people
  • SchiltachSchiltach, GermanyTaking people
  • SchneverdingenSchneverdingen, GermanyTaking people
  • Schwäbisch HallSchwäbisch Hall, GermanyTaking people
  • SchwetzingenSchwetzingen, GermanyTaking people
  • SiegenSiegen, GermanyNo longer taking part
  • SinsheimSinsheim, GermanyTaking people
  • StadtrodaStadtroda, GermanyTaking people
  • StuttgartStuttgart, GermanyNo longer taking part
  • TirschenreuthTirschenreuth, GermanyTaking people
  • TrierTrier, GermanyTaking people
  • TübingenTübingen, GermanyTaking people
  • UnterhachingUnterhaching, GermanyNo longer taking part
  • UntermeitingenUntermeitingen, GermanyTaking people
  • VelbertVelbert, GermanyTaking people
  • Weil der StadtWeil der Stadt, GermanyTaking people
  • WildeshausenWildeshausen, GermanyNo longer taking part
  • WolfratshausenWolfratshausen, GermanyNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Novartis Pharmaceuticals
Trial code
NCT05344469
Record updated
30 July 2026
Original description
This is an observational, non-interventional, multicenter, open-label study in patients being treated with any approved injectable or selected oral DMT for RMS in Germany.Read full original descriptionShow less

A Non-interventional Study Evaluating Injectable Treatments (Ofatumumab, Glatiramer Acetate and Interferon β1) and Oral Treatments (Teriflunomide, Dimethyl Fumarate and Diroximel Fumarate) in Patients With Relapsing Multiple Sclerosis [AIOLOS]

This is an observational, non-interventional, multicenter, open-label study in patients being treated with any approved injectable or selected oral DMT for RMS in Germany.

Prospective, primary data will be collected via questionnaires and an electronic case report form (eCRF) over a period of up to four years. Additionally, medical history of participants will be collected including disease duration, laboratory values, EDSS, MRI parameters and relapses.

Cohort 1 Inclusion Criteria:; Signed informed consent must be obtained prior to participation in the study; Male or female patients aged ≥18 years at enrollment; Diagnosis of MS according to the 2017 revised McDonald criteria (Thompson et al 2018b); RMS with active disease as defined by Lublin et al. (2014); Max. 1 relapse during the previous year and max. 2 relapses during the previous two years prior to enrollment; Disability status at enrollment with an EDSS score of 0 to 2.5 (inclusive); Planned initiation or initiation within the past 14 days with an approved injectable DMT for MS as routine medical treatment; Cohort 2 Inclusion Criteria:; Signed informed consent must be obtained prior to participation,; Male or female patients aged ≥18 years at enrollment,; Diagnosis of MS according to the 2024 revised McDonald criteria (Montalban et al., 2025),; RMS with active disease as defined by Lublin et al. (2014) ,; Max. 1 relapse during the previous year and max. 2 relapses during the previous two years prior to enrollment,; Disability status at enrollment with an EDSS score of 0 to 3.0 (inclusive),; Planned initiation or initiation within the past 14 days with an approved injectable or oral DMT for MS as routine medical treatment:; Ofatumumab: only naïve patients or patients previously treated with max. one DMT other than ofatumumab; IFN-β1, GA, teriflunomide, DMF or DRF: only naïve patients; Cohort 1 Exclusion Criteria:; Patients being treated outside of the approved label; > 5 years since first symptom(s) (leading to MS diagnosis) at enrollment; Previous therapy with any DMT for the treatment of MS prior to enrollment (except within the past 14 days with an approved injectable DMT for MS as routine medical treatment; see Inclusion criteria #7); Relapse prior to enrollment which has led to a severe deficit relevant to everyday life upon discretion of the investigator after exhaustion of the relapse therapy; Poor recovery from the first two relapses prior to enrollment upon discretion of the investigator; EDSS Functional System Score "Pyramidal Functions" ≥ 2 at enrollment; Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with Ofatumumab; Cohort 2 Exclusion Criteria:; Patients being treated outside of the approved label,; >5 years since first symptom(s) (leading to MS diagnosis) at enrollment,; Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with Ofatumumab,; Patients being previously enrolled in cohort 1 are not eligible to be enrolled into cohort 2.

ClinicalTrials.gov NCT05344469